Myo-inositol may prevent gestational diabetes in PCOS women
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate retrospectively the prevalence of gestational diabetes (GD) in pregnancies obtained with myo-inositol administration in women with polycystic ovary syndrome. A total of 98 pregnancies in PCOS women obtained in a 3-year period, either with myo-inositol (n. 54), or with metformin (n. 44) were considered. While myo-inositol was assumed through the whole pregnancy, the group of women treated with metformin stopped the drug assumption after pregnancy diagnosis, and was considered as a control group. After having eliminated cases of miscarriages and twin pregnancies, a definitive number of 46 women in the myo-inositol group and 37 in the control group was taken in account to be retrospectively evaluated. The primary outcome measure was GD occurrence in both groups; whereas secondary outcome measures were pregnancy outcomes: hypertensive disorders, pre-term birth, macrosomia and caesarean section occurrence. Prevalence of GD in the myo-inositol group was 17.4% versus 54% in the control group, with a highly significant difference also after adjusting for covariates. Consequently, in the control group the risk of GD occurrence was more than double compared to the myo-inositol group, with an odds ratio 2.4 (confidence interval 95%, 1.3-4.4). There was no difference between the groups in relation to secondary outcome measures. This study suggests a possible effect of myo-inositol in the primary prevention of GD in PCOS women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Criteria for screening tests for gestational diabetes
Carpenter, M. W., & Coustan, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90349-0 · Cited by 1,924
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518
Vanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315 · cited 2×
“Similar results were obtained in a larger multicenter study in which metformin was used [14]; whereas in the Katthab et al.”
BackgroundResultGenazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · cited 1×
“Inositol was described as a second messenger system that may exert an insulin-like effect on metabolic enzymes [6]; for this action, inositol has been reported to improve insulin sensitivity and ovulatory function in young women affected by PCOS, both in the isoform D-chiro-inositol [7], and in the isoform myoinositol…”
Background
Cited by
Matarrelli, B., Vitacolonna, E., D’angelo, M., Pavone, G., Mattei, P. A., Liberati, M., & Celentano, C. (2013) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2013.766691 · Cited by 114
“described myo-inositol as safe during the pre-pregnancy and early pregnancy period in insulin-resistant conditions [7].”
BackgroundUnfer, V., Carlomagno, G., Papaleo, E., Vailati, S., Candiani, M., & Baillargeon, J.-P. (2014) · Reproductive Sciences · doi:10.1177/1933719113518985 · Cited by 105
“An additional inclusion criterion for women with PCOS was hyperinsulinemia defined as fasting insulin higher than 10 mU/mL.(18,19)”
BackgroundKamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
Inositol and human reproduction. From cellular metabolism to clinical use
Milewska, E. M., Czyzyk, A., Meczekalski, B., & Genazzani, A. D. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1188282 · Cited by 69
“MI use in the primary prevention of gestational diabetes mellitus in PCOS women [15].”
MethodCelentano, C., Matarrelli, B., Pavone, G., Vitacolonna, E., Mattei, P. A., Berghella, V., & Liberati, M. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1500545 · Cited by 54
Metadata
- Authors
- D’Anna, R., Di Benedetto, V., Rizzo, P., Raffone, E., Interdonato, M. L., Corrado, F., & Di Benedetto, A.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2011-11-28
- Volume
- 28
- Issue
- 6
- Pages
- 440-442
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2152590838
- Cited by
- 95
- References
- 4
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myo-inositol may prevent gestational diabetes in PCOS women. https://app.cochat.ai/papers/10.3109/09513590.2011.633665
- The paper
- D’Anna, R., Di Benedetto, V., Rizzo, P., Raffone, E., Interdonato, M. L., Corrado, F., & Di Benedetto, A. (2012). Myo-inositol may prevent gestational diabetes in PCOS women. Gynecological Endocrinology. https://doi.org/10.3109/09513590.2011.633665
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.